Peripheral Blood DNA Methylation-Based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biologic Specimens and Data From the Osteoarthritis Initiative and Johnston County Osteoarthritis Project.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
01 2023
Historique:
revised: 08 07 2022
received: 09 05 2022
accepted: 20 07 2022
pmc-release: 01 01 2024
pubmed: 22 11 2022
medline: 30 12 2022
entrez: 21 11 2022
Statut: ppublish

Résumé

The lack of accurate biomarkers to predict knee osteoarthritis (OA) progression is a key unmet need in OA clinical research. The objective of this study was to develop baseline peripheral blood epigenetic biomarker models to predict knee OA progression. Genome-wide buffy coat DNA methylation patterns from 554 individuals from the Osteoarthritis Biomarkers Consortium (OABC) were determined using Illumina Infinium MethylationEPIC 850K arrays. Data were divided into model development and validation sets, and machine learning models were trained to classify future OA progression by knee pain, radiographic imaging, knee pain plus radiographic imaging, and any progression (pain, radiographic, or both). Parsimonious models using the top 13 CpG sites most frequently selected during development were tested on independent samples from participants in the Johnston County Osteoarthritis (JoCo OA) Project (n = 128) and a previously published Osteoarthritis Initiative (OAI) data set (n = 55). Full models accurately classified future radiographic-only progression (mean ± SEM accuracy 87 ± 0.8%, area under the curve [AUC] 0.94 ± 0.004), pain-only progression (accuracy 89 ± 0.9%, AUC 0.97 ± 0.004), pain plus radiographic progression (accuracy 72 ± 0.7%, AUC 0.79 ± 0.006), and any progression (accuracy 78 ± 0.4%, AUC 0.86 ± 0.004). Pain-only and radiographic-only progressors were not distinguishable (mean ± SEM accuracy 58 ± 1%, AUC 0.62 ± 0.001). Parsimonious models showed similar performance and accurately classified future radiographic progressors in the OABC cohort and in both validation cohorts (mean ± SEM accuracy 80 ± 0.3%, AUC 0.88 ± 0.003 [using JoCo OA Project data], accuracy 80 ± 0.8%, AUC 0.89 ± 0.002 [using previous OAI data]). Our data suggest that pain and structural progression share similar early systemic immune epigenotypes. Further studies should focus on evaluating the pathophysiologic consequences of differential DNA methylation and peripheral blood cell epigenotypes in individuals with knee OA.

Identifiants

pubmed: 36411273
doi: 10.1002/art.42316
pmc: PMC9797424
mid: NIHMS1827216
doi:

Substances chimiques

Biomarkers 0
Biological Products 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

28-40

Subventions

Organisme : NIAMS NIH HHS
ID : K08 AR070891
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR076440
Pays : United States
Organisme : NIAMS NIH HHS
ID : R61 AR078075
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20GM125528
Pays : United States

Informations de copyright

© 2022 American College of Rheumatology.

Références

J Rheumatol. 2007 Jan;34(1):172-80
pubmed: 17216685
Osteoarthritis Cartilage. 2013 Jan;21(1):117-25
pubmed: 23128183
Front Genet. 2018 Aug 30;9:246
pubmed: 30214455
Ann Rheum Dis. 2021 Aug;80(8):1062-1069
pubmed: 33962962
Arthritis Rheumatol. 2015 Dec;67(12):3184-9
pubmed: 26316262
Arthritis Rheumatol. 2014 Oct;66(10):2804-15
pubmed: 24980887
Genome Biol. 2016 May 03;17:84
pubmed: 27142380
Ann Rheum Dis. 2017 Jan;76(1):186-195
pubmed: 27296323
Arthritis Rheumatol. 2016 Jun;68(6):1403-14
pubmed: 26713865
Arthritis Res Ther. 2020 Sep 10;22(1):208
pubmed: 32912331
MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):869-73
pubmed: 24196662
BMC Bioinformatics. 2012 May 08;13:86
pubmed: 22568884
Osteoarthritis Cartilage. 2017 Jul;25(7):1114-1121
pubmed: 28216313
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Circulation. 2011 May 17;123(19):2145-56
pubmed: 21576679
Arthritis Rheumatol. 2018 Jan;70(1):80-87
pubmed: 29024470
Semin Arthritis Rheum. 2019 Jun;48(6):950-957
pubmed: 30390991
Sci Rep. 2019 Nov 14;9(1):16880
pubmed: 31727952
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Ann Rheum Dis. 2016 Sep;75(9):1607-14
pubmed: 26483253
Arthritis Care Res (Hoboken). 2021 Sep;73(9):1354-1362
pubmed: 32491247
PeerJ. 2014 Sep 23;2:e561
pubmed: 25332844
BMC Bioinformatics. 2017 Apr 14;18(1):216
pubmed: 28410574
Nat Commun. 2019 Oct 25;10(1):4898
pubmed: 31653858
Arthritis Rheumatol. 2014 Sep;66(9):2450-60
pubmed: 24838673
Arthritis Care Res (Hoboken). 2022 Jul;74(7):1142-1153
pubmed: 33421361
J Rheumatol. 2009 Jan;36(1):141-55
pubmed: 19040300
Ann Rheum Dis. 2014 Dec;73(12):2208-12
pubmed: 25261579
Best Pract Res Clin Rheumatol. 2014 Feb;28(1):61-71
pubmed: 24792945
Arthritis Rheumatol. 2016 Oct;68(10):2422-31
pubmed: 27111771
Biostatistics. 2019 Apr 1;20(2):273-286
pubmed: 29394327
Ann Rheum Dis. 2014 Apr;73(4):668-77
pubmed: 23505229
Osteoarthritis Cartilage. 2019 Jul;27(7):994-1001
pubmed: 31002938
Nucleic Acids Res. 2017 Feb 28;45(4):e22
pubmed: 27924034
BMC Musculoskelet Disord. 2020 May 29;21(1):332
pubmed: 32471412

Auteurs

Christopher M Dunn (CM)

Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine, University of Oklahoma Health Sciences Center, and Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Cassandra Sturdy (C)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Cassandra Velasco (C)

Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine, University of Oklahoma Health Sciences Center, and Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Leoni Schlupp (L)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Emmaline Prinz (E)

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Vladislav Izda (V)

Icahn School of Medicine at Mount Sinai, New York, New York.

Liubov Arbeeva (L)

Thurston Arthritis Research Center, University of North Carolina at Chapel Hill.

Yvonne M Golightly (YM)

College of Allied Health Professions, University of Nebraska Medical Center, Omaha.

Amanda E Nelson (AE)

Thurston Arthritis Research Center, University of North Carolina at Chapel Hill.

Matlock A Jeffries (MA)

Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine, University of Oklahoma Health Sciences Center, and Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH